Figure S1 from Preclinical Comparison of the Blood–brain Barrier Permeability of Osimertinib with Other EGFR TKIs

Nicola Colclough,Kan Chen,Peter Johnström, Nicole Strittmatter, Yumei Yan,Gail L. Wrigley,Magnus Schou,Richard Goodwin,Katarina Varnäs, Sally J. Adua, Minghui Zhao,Don X. Nguyen,Gareth Maglennon, Peter Barton,James Atkinson, Lin Zhang,Annika Janefeldt,Joanne Wilson, Aaron Smith,Akihiro Takano, Ryosuke Arakawa,Mikhail Kondrashov, Jonas Malmquist, Evgeny Revunov,Ana Vazquez-Romero, Mohammad Mahdi Moein, Albert D. Windhorst,Natasha A. Karp, M. Raymond V. Finlay,Richard A. Ward, James W.T. Yates, Paul D. Smith,Lars Farde, Zack Cheng,Darren A.E. Cross

crossref（2023）

引用 0|浏览0

暂无评分

摘要

Supplementary Figure S1 - Structure and position of label for compounds assessed for BBB penetrance in non human primates (NHP). Majority of compounds were labelled with carbon-11 except afatinib which was labelled with fluorine-18. (*) Indicates position for carbon-11 label

查看译文

关键词

Biomarker Analysis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要